27 Sep 2018 07:01
27 September 2018
Concepta PLC
("Concepta" or the "Company")
Directorate change
As set out in the Interim Results announcement issued earlier today, the Company is pleased to announce the appointment of Dr David Darrock, Chief Operating Officer, as a Director of the Concepta plc board.
Dr Darrock's full name is David John Darrock, he is 40 years old.
The following disclosures are made in line with the AIM Rules for Companies:
Current directorships/partnerships: None
Directorships and partnerships held within the last five years: None
Shareholding : Dr Darrock holds no shares in the Company; and holds options over 1,000,000 shares at an exercise price of 5.95 pence per share.
Save for the information set out above, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Dr David Darrock.
Enquiries:
The Company
Matthew Walls, Chairman Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury +44 (0) 20 7399 9400
Yellow Jersey PR Limited (Financial PR)
Georgia Colkin / Joe Burgess/Katie Bairsto Tel: +44 (0) 776 932 5254
About Concepta PLC:
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on fertility and unexplained infertility† in women.
myLotus is currently the only consumer product which allows both quantitative and qualitative home (self test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus is to help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company anticipates receiving CE-mark certification for myLotus over the coming months and is preparing its B2C launch in the UK and Europe. The Company has identified a significant global market opportunity with revenue potential of the EU and Chinese unexplained infertility market estimated to be worth c.£600m per annum.
Concepta has also made progress in establishing relationships with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the B2C route in the near future.
†Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.